Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer
HONG KONG, Feb. 24, 2022 /PRNewswire/ -- On February 23 2022, Simcere Pharmaceutical Group (2096.HK) announced that the phase III clinical registration study of Trilaciclib in patients with extensive-stage small cell lung cancer (ES-SCLC) has met its primary endpoint. The drug co-developed in China by Simcere and G1 Therapeutics is the world's first comprehensive myeloprotective drug in treating ES-SCLC....
Learn More About Tobacco Packaging From TPackSS Website
BALTIMORE, Feb. 24 2022 /PRNewswire/ -- Anyone can take an active role in the local tobacco control effort by using or contributing to the Tobacco Pack Surveillance System (TPackSS). Developed by the Institute for Global Tobacco Control at the Johns Hopkins Bloomberg School of Public Health, TPackSS features a searchable database of over 6,600 tobacco packs collected from...
Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China
BEIJING, SHANGHAI and BOSTON, Feb. 24, 2022 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) announced that its KRAS G12C inhibitor JAB-21822 completed the first patient dosing in combination therapy with Cetuximab at Peking University Cancer Hospital recently. JAB-21822 in combination with cetuximab for the treatment of KRAS G12C-mutated advanced colorectal cancer. Colorectal cancer is...
Alphamab Oncology Announced Publication of Clinical Results of KN026 in HER2-positive Breast Cancer in Clinical Cancer Research
SUZHOU, China, Feb. 24, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR), published the data from a phase I clinical study of the company's proprietary HER2 bispecific antibody KN026 for the treatment of HER2-positive metastatic breast cancer ("First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment...
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
SAN FRANCISCO and SUZHOU, China, Feb. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announces that the first patient has been successfully dosed in the phase 1, first-in-human clinical trial of its proprietary CD73...
CSafe Global Announces Appointment of New Board Member
DAYTON, Ohio, Feb. 24, 2022 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled container solutions for the transport of life-enhancing pharmaceuticals, announced today that Joe Newell has been appointed to the company's board of directors. With this appointment the Board will comprise 9 directors. Joe Newell, Atara Biotherapeutics COO...
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
TAIPEI, Feb. 23, 2022 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), a Taiwan and US-based biopharmaceutical company and TRPharm, a leading Turkish healthcare company, announced today that they have entered into an exclusive license agreement for the co-development and commercialisation in Turkey and certain MENA countries of Foresee's FP-045 program, an oral allosteric Aldehyde Dehydrogenase 2 (ALDH2) activator for...
Orpha Labs AG Announces the Initiation of a Phase III Trial Evaluating ORL-101 for Treatment of Leukocyte Adhesion Deficiency Type II
BAAR, Switzerland, Feb. 23, 2022 /PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III trial with ORL-101 in patients with Leukocyte Adhesion Deficiency Type II ("LAD-II"). Orpha Labs AG is working with investigators to switch patients from a compassionate...
SyMap Medical Ltd Completed Enrollment in SMART Study for the Treatment of Uncontrolled Hypertension
SUZHOU, China, Feb. 23, 2022 /PRNewswire/ -- SyMap Medical Ltd. (Suzhou, China) announced successful completion of enrollment in the company's SMART Study (Sympathetic Mapping/Ablation Renal nerves for Treatment of hypertension Trial; NCT02761811), using the SyMapCath I™ Catheter/SYMPIONEER S1™ Mapping/RF System for the treatment of uncontrolled hypertension. This is the first pivotal...
Identi Medical Wins the Frost & Sullivan Product Innovation Award for Increasing Inventory Visibility in Operating Rooms Using Image Recognition
Identi Medical helps hospitals provide safer care for their patients with its highly differentiated inventory management solutions for operating and procedural rooms SAN ANTONIO, Feb. 23, 2022 /PRNewswire/ -- Based on its recent analysis of the European Operating Room Inventory Management Solutions Industry, Frost & Sullivan recognizes Identi Medical (Identi) with the 2022...
